Department of Pathology fully-funded PhD studentships: project proposal form

<table>
<thead>
<tr>
<th>Division</th>
<th>Cellular and Molecular Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supervisor</td>
<td>Nicholas Coleman</td>
</tr>
<tr>
<td>Project title</td>
<td>MicroRNA dysregulation in malignant germ cell tumours: more than a biomarker?</td>
</tr>
<tr>
<td>Project abstract for advert</td>
<td>Malignant germ cell tumours (mGCTs) are the most common cause of cancer deaths in young adult males. Our group discovered that all mGCTs, despite being clinically and pathologically variable, are characterised by specific abnormalities in microRNA levels. This important finding has led to the development of widely-adopted blood tests for mGCT diagnosis and monitoring. The current project will investigate whether the microRNA changes can also be targeted as new biological therapies for mGCTs. Initial work will involve the generation of inducible lentivirus constructs for replenishment of tumour suppressor microRNAs and depletion of oncogenic microRNAs in established tumours. The effects of rectified microRNA expression will then be investigated using multiple in vivo model systems. The ultimate aim is to progress the work to first-in-man clinical trials.</td>
</tr>
<tr>
<td>Full details</td>
<td>Malignant germ cell tumours (mGCTs) are clinico-pathologically heterogeneous tumours that are the most common cause of cancer deaths in young adult males. In 2010, we identified changes in microRNA expression levels that were seen in all malignant GCTs, regardless of patient age, tumour site or histologic subtype. The most significant were coordinate over-expression of the oncogenic miR-371<del>373 and miR-302/367 clusters and under-expression of the tumour suppressors miR-99a/100 and miR-125b (see Figure). Multiple international studies have confirmed our findings that quantification of serum levels of miR-371</del>373 and miR-302/367 microRNA improve mGCT diagnosis. It is widely predicted that this approach will enter routine clinical use world-wide in the next 2-3 years. The current project will test the hypothesis that the dysregulated microRNAs represent important therapeutic targets in mGCTs. Many of the microRNAs share the same functional 'seed' at nt 2-7, leading to deregulation of mRNA targets and recapitulation of a stem cell phenotype. The project will use inducible systems for in vivo manipulation of microRNA levels in a panel of luciferase-labelled mGCT cell lines representing all major histological types. We have generated tetracycline-inducible lentiviral vectors for increasing expression levels of miR-99a/100 and 125b, either singly or in combination, and will derive inducible shRNA vectors for reducing levels of miR-371~373/miR-302/367. After in vitro characterisation, the student will quantify the effects of inducing tumour suppressor microRNAs and/or depleting oncogenic microRNAs on established subcutaneous, testicular orthotopic and metastatic lung tumours in nude mice. Readouts will include tumour morphology and mRNA expression profiling, including measurement of direct miRNA effects using the Sylamer algorithm (Enright lab). In due course, the work will be extended using patient-derived xenografts and nanoparticle delivery, with the aim of progressing to first-in-man trials via our collaboration with the Cambridge Clinical Trials Unit.</td>
</tr>
</tbody>
</table>
### Image(s) related to project

Image reproduced from recent publication 1 (see below)

### Malignant Germ Cell Tumor

- **Over-expressed (oncogenic) miRNAs**
  - miR-371~373
  - miR-302/367

- **Under-expressed (tumor suppressor) miRNAs**
  - miR-99a
  - miR-100
  - miR-125b

- **? Transcription factor(s)**

- **? Epigenetic e.g. DNA methylation**

- **High LIN28 levels**

- **let-7**

- **Novel biomarkers**

- **Targeting oncogenic miRNAs**

- **Dysregulation of cellular processes**

- **Repression of mRNA targets e.g. LATS2, GSTM3, NKX3-1**

- **Replenishing tumor suppressor miRNAs**

### 5 recent publications


4. Groves IJ, Knight ELA, Ang QY, Scarpini CG, Coleman N (2016) HPV16 oncogene expression levels during early cervical carcinogenesis are determined by the balance of epigenetic chromatin modifications at the integrated virus genome. *Oncogene* 35:4773-86.